XORTX Therapeutics (XRTX) Financials

$1.92

$0.26 (15.66%)

As on 18-Sep-2026 16:29EDT

Market cap

$3 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.10	0.11	0.11	0.14	0.07	0.02
Gross Profit	-0.10	-0.11	-0.11	-0.14	-0.07	-0.02
Operating Expenses	3.90	3.26	3.81	6.05	12.43	3.66
Operating Profit (EBIT)	-3.93	-3.26	-3.92	-6.05	-12.43	-3.68
Other Income	--	--	--	--	--	--
Profit before Tax	-3.75	-2.66	-3.15	-2.16	-10.45	-1.66
Provision for Tax	--	--	--	--	--	0.00
Profit after Tax (Net Income)	-3.75	-2.66	-3.15	-2.16	-10.45	-1.66
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-9.49	-1.65

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	5.50	2.08	3.34	4.64	7.00	13.20
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	--	0.53	3.87	3.63
Current Liabilities	0.68	0.60	0.76	0.83	1.51	0.55
Total Liabilities	6.86	2.68	4.09	5.47	12.37	17.38

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	3.74	1.71	1.42	1.40	1.48	1.47
Current Assets	2.43	0.97	2.68	4.07	10.90	15.91
Total Assets	6.85	2.68	4.09	5.47	12.37	17.38
Total Debt*	--	0.04	0.04	0.01	0.08	--
Net Current Assets	1.76	0.66	1.92	3.77	9.36	14.88

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-2.82	-3.68	-6.58	-8.17	-4.80
Cash Flow from Investing Activities	--	-0.30	-0.04	-0.05	-0.05	-0.03
Cash from Financing Activities	--	1.45	2.78	-0.36	3.91	19.37
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-2.75	-2.02	-23.84	-26.98	-164.32	-30.38
Cash EPS ($)	-2.58	-1.94	-22.96	-25.23	-163.45	-30.05
Adjusted Book Value ($)	1.50	1.59	25.22	58.03	110.01	240.92
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-2.15	-27.81	-82.29	-128.40	-87.61
Free Cash Flow per Share ($)	--	-2.15	-28.10	-82.87	-141.66	-88.19

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-96.71	-78.57	-36.80	-103.08	-23.03
ROE (%)	-98.86	-98.07	-79.07	-37.08	-103.48	-23.03
ROA (%)	-72.73	-78.44	-65.97	-24.19	-70.24	-16.93
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-15.87	16.95	35.15	51.68	-328.37	-164.89
Net Profit Growth (%)	-99.28	15.79	-46.16	79.35	-527.74	-29.60
EPS Growth (%)	-137.57	0.92	0.12	0.84	-4.41	0.27
Book Value Growth (%)	26.80	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.28	-0.05	-0.09	-0.04	-0.61
Price / Book Value	0.55	0.35	0.04	0.04	0.07	0.08
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.09	0.03	0.60	0.55	0.79	4.74
Close Price ($)	2.17	2.81	5.65	11.55	2,945.16	7,472.25
High Price ($)	7.05	8.95	35.00	4,519.80	9,039.60	22,307.40
Low Price ($)	1.73	2.55	5.35	9.90	2,416.64	0.45
Market Cap ($ Cr)	3.49	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.02	0.01	0.00	0.01	--
Short term debt to equity ratio	--	0.02	0.01	0.00	0.01	--
Current Ratio	3.59	1.61	3.53	4.93	7.21	28.78
Quick Ratio	3.59	--	--	4.63	7.30	29.27
Interest Coverage	--	--	--	--	--	-519.00

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	811.17	144.89	-1,002.11	-2,891.99
Payable days	--	767.72	457.75	1,916.36	3,960.12	7,236.71
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.